Overview

Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma

Status:
Unknown status

Trial end date:
2019-12-01

Target enrollment:
0

Participant gender:
All

Summary

Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection. To date, adjuvant chemotherapy or other adjuvant modalities have not been proven effective in preventing or delaying recurrence. The aim of this prospective randomized study was to evaluate the effectiveness of Thalidomide as a postoperative adjuvant regimen in inhibiting the recurrence of HCC

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

The First Affiliated Hospital of Xiamen University

Treatments:

Thalidomide

Criteria

Inclusion Criteria:

1. 18-75 years old,male and female

2. Patients who did not receive any anti-tumor therapies prior to the surgery (including
liver transplantation, TACE, local tumor ablation, chemotherapy, radiotherapy,
molecular targeted therapy and other anti-tumor therapy) resection of hepatocellular
carcinoma

3. Patients who underwent radical resection of HCC, and 1 month after surgery,dynamic
computed tomography showed on lesion in the liver and no signs of extrahepatic
metastasis

4. Sign the informed consent

Exclusion Criteria:

1. Women who were pregnant or breast-feeding

2. signs showing recurrence or metastasis one month after surgery

3. Recurrent HCC

4. Patients unable to take drug orally

5. Patients inappropriate to participate in the trial upon the investigator's judgment